Product Name |
CDK1 |
CDK2 |
CDK3 |
CDK4 |
CDK5 |
CDK6 |
CDK7 |
CDK8 |
CDK9 |
CDK11 |
CDK12 |
CDK13 |
CDK14 |
CDK16 |
CDK19 |
CDC |
CLK |
Pho85 |
Purity |
Palbociclib |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
Abemaciclib |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
|
|
|
|
|
|
99.97% |
Ribociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
Ro-3306 |
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
Dinaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
Flavopiridol |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
GSK3326595 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
Palbociclib monohydrochloride |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
(R)-Roscovitine |
cdc2/cyclin B, IC50: 0.65 μM
|
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
Abemaciclib methanesulfonate |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
|
|
|
|
|
|
99.95% |
THZ1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
AZD4573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
THZ531 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
Palbociclib isethionate |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
Kenpaullone |
Cdk1/cyclin B, IC50: 0.4 μM
|
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
Atirmociclib |
|
|
|
Cdk4/cyclin D1, Ki: 0.6 nM
|
|
cdk6/cyclin D3, Ki: 13.9 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
SR-4835 |
|
|
|
|
|
|
|
|
|
|
CDK12, IC50: 99 nM
CDK12, Kd: 98 nM
|
|
|
|
|
|
|
|
99.73% |
SY-5609 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
Toyocamycin |
|
CDK2/cyclinA, IC50: 0.67 μM
|
|
Cdk4/cyclin D3, IC50: 15 μM
|
|
cdk6/cyclin D3, IC50: >10 μM
|
CDK7/Mat1/cyclinH1, IC50: 2.8 μM
|
|
CDK9/cyclinT1, IC50: 79 nM
|
|
|
|
|
|
|
|
|
|
99.90% |
SNS-032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
Wogonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
GSK 3 Inhibitor IX |
Cdk1/cyclin B, IC50: 320 nM
|
cdk2/cyclin A, IC50: 300 nM
|
|
Cdk4/cyclin D1, IC50: 10 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
Amantadine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
OTS964 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
NVP-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
Samuraciclib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
Palbociclib hydrochloride |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
Simurosertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
JNJ-7706621 |
Cdk1/cyclin B, IC50: 9 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
CDK3/Cyclin E, IC50: 58 nM
|
Cdk4/cyclin D1, IC50: 253 nM
|
|
CDK6/cyclinD1, IC50: 175 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
AT7519 |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
|
99.76% |
KB-0742 dihydrochloride |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 6 nM
|
|
|
|
|
|
|
|
|
|
99.24% |
(+)-Enitociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
hSMG-1 inhibitor 11j |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
MBQ-167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
Tagtociclib hydrate |
|
CDK2/cyclin E1, Ki: 1.16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
Fadraciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
CPS2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
BI-1347 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
BSJ-4-116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.73% |
Ribociclib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
Flavopiridol Hydrochloride |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
TG003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 20 nM
CLK2, IC50: 200 nM
CLK4, IC50: 15 nM
|
|
99.57% |
AZD-5438 |
cdk1-cyclin B1, IC50: 16 nM
|
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
|
|
cdk4-cyclin D1, IC50: 449 nM
|
|
cdk6-cyclin D3, IC50: 21 nM
|
cdk7-cyclin H, IC50: 821 nM
|
|
cdk9-cyclin T, IC50: 20 nM
|
|
|
|
|
|
|
|
|
|
99.85% |
AS2863619 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
TL12-186 |
|
cdk2/cyclin A, IC50: 73 nM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 55 nM
|
|
|
|
|
|
|
|
|
|
99.63% |
Ribociclib succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
CVT-313 |
Cdk1/cyclin B, IC50: 4.2 μM
|
cdk2/cyclin A, IC50: 0.5 μM
|
|
Cdk4/cyclin D1, IC50: 215 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
NG 52 |
cdc2-cyclin B, IC50: 0.34 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
YKL-5-124 |
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
CLK-IN-T3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 0.67 nM
CLK2, IC50: 15 nM
CLK3, IC50: 110 nM
|
|
98.63% |
BSJ-03-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
MSC2530818 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
(E/Z)-Zotiraciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
SEL120-34A monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
|
99.29% |
(R)-CR8 |
Cdk1/cyclin B, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
|
|
|
|
|
|
99.61% |
XL413 monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
CGP60474 |
CDK1-Cyclin B, IC50: 26 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
|
CDK4/cyclin D, IC50: 216 nM
|
|
|
CDK7/cyclin H, IC50: 200 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
AUZ 454 |
|
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
hSMG-1 inhibitor 11e |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
CTX-712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
BSJ-04-132 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
PROTAC CDK2/9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
Mevociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
Cucurbitacin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
Nimbolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
BTX-A51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
Ebvaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
FMF-04-159-2 |
|
CDK2, IC50: 256 nM (in NanoBRET assay)
|
|
|
|
|
|
|
|
|
|
|
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
|
|
|
|
|
|
99.48% |
Roniciclib |
Cdk1/cyclin B, IC50: 7 nM
|
|
|
CDK4/cyclin D, IC50: 11 nM
|
|
|
CDK7/Cyclin H/MAT1, IC50: 25 nM
|
|
CDK9/cyclinT1, IC50: 5 nM
|
|
|
|
|
|
|
|
|
|
98.09% |
BSJ-03-204 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
CCT-251921 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
Milciclib |
cyclin B/CDK1, IC50: 398 nM
|
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
|
|
cyclin D1/CDK4, IC50: 160 nM
|
|
|
cyclin H/CDK7, IC50: 150 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
Abemaciclib metabolite M2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
PF 477736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
XY028-140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.42% |
LDC000067 |
cdk1-cyclin B1, IC50: 5513 nM
|
cdk2-cyclin A, IC50: 2441 nM
|
|
cdk4-cyclin D1, IC50: 9242 nM
|
|
|
|
|
CDK9- Cyclin T1, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
98.09% |
NU6300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THZ1 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
Purvalanol A |
cdc2-cyclin B, IC50: 4 nM
|
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
|
|
cdk4-cyclin D1, IC50: 850 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
T025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, Kd: 4.8 nM
CLK2, Kd: 0.096 nM
CLK3, Kd: 6.5 nM
CLK4, Kd: 0.61 nM
|
|
98.84% |
BMS-265246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
PHA-767491 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
Senexin A |
|
|
|
|
|
|
|
CDK8, Kd: 0.83 μM
CDK8, IC50: 280 nM
|
|
|
|
|
|
|
|
|
|
|
99.79% |
R547 |
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
|
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
|
CDK3/Cyclin E, IC50: 0.8 nM
|
|
|
cdk6/cyclin D3, IC50: 4 nM
|
CDK7/cyclin H, IC50: 171 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
Amantadine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
Lerociclib dihydrochloride |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
|
|
|
|
|
|
98.11% |
(R)-CR8 trihydrochloride |
CDK1/cyclinB1, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
|
|
|
|
|
|
98.95% |
Asnuciclib |
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
|
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
|
|
|
|
|
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
|
|
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
|
|
|
|
|
|
|
|
|
|
99.76% |
BS-181 hydrochloride |
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
CDK12-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
SU9516 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
Trilaciclib hydrochloride |
|
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
|
cdk6/cyclin D3, IC50: 4 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
THZ2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
Atuveciclib |
CDK1/CycB(h), IC50: 1100 nM
|
CDK2/CycE(h), IC50: 1000 nM
|
CDK3/CycE(h), IC50: 890 nM
|
|
CDK5/p35(h), IC50: 1600 nM
|
|
|
|
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
|
|
|
|
|
|
|
|
|
|
99.80% |
CDK2-IN-4 |
Cdk1/cyclin B, IC50: 86 μM
|
cdk2/cyclin A, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
JSH-150 |
Cdk1/cyclin B, IC50: 1.34 μM
|
cdk2/cyclin A, IC50: 2.86 μM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
|
|
CDK9/cyclinT1, IC50: 1 nM
|
|
|
|
CDK14/Cyclin Y, IC50: 1.68 μM
|
CDK16/Cyclin Y, IC50: 292 nM
|
|
|
|
|
98.36% |
Purvalanol B |
cdc2/cyclin B, IC50: 6 nM
|
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BRD6989 |
|
|
|
|
|
|
|
CDK8, IC50: ~200 nM
recombinant CDK8, IC50: ~0.5 μM
|
|
|
|
|
|
|
recombinant CDK19, IC50: >30 μM
|
|
|
|
99.56% |
Narazaciclib |
|
|
|
Cdk4/cyclin D1, IC50: 3.9 nM
|
|
CDK6/cyclinD1, IC50: 9.82 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
GFB-12811 |
|
|
|
|
|
|
CDK7/Cyclin H/MAT1, IC50: 718 nM
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
Abemaciclib metabolite M18 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
CDK5 inhibitor 20-223 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
Thiabendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
CDK12-IN-2 |
|
|
|
|
|
|
CDK7, IC50: >10 μM
CDK7, IC50: >10 μM
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
CP-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
TC11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.04% |
PHA-793887 |
Cdk1/cyclin B, IC50: 60 nM
|
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
|
|
Cdk4/cyclin D1, IC50: 62 nM
|
|
|
CDK7/cyclin H, IC50: 10 nM
|
|
CDK9/cyclinT1, IC50: 138 nM
|
|
|
|
|
|
|
|
|
|
99.25% |
MC180295 |
CDK1-Cyclin B, IC50: 138 nM
|
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
|
CDK3-Cyclin E, IC50: 399 nM
|
CDK4-Cyclin D, IC50: 112 nM
|
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
|
cdk6-cyclin D3, IC50: 712 nM
|
CDK7-CycH/MAT1, IC50: 555 nM
|
|
CDK9- Cyclin T1, IC50: 5 nM
|
|
|
|
|
|
|
|
|
|
98.89% |
PROTAC CDK9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
FN-1501 |
|
cdk2/cyclin A, IC50: 2.47 nM
|
|
Cdk4/cyclin D1, IC50: 0.85 nM
|
|
CDK6/cyclinD1, IC50: 1.96 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
CDK12-IN-E9 |
|
cdk2/cyclin A, IC50: 932 nM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
|
|
CDK9/cyclinT1, IC50: 23.9 nM
|
|
|
|
|
|
|
|
|
|
99.97% |
CKI-7 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
LY2857785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
Abemaciclib metabolite M20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RGB-286638 |
cyclin B1-CDK1, IC50: 2 nM
|
cyclin E-CDK2, IC50: 3 nM
|
cyclin E-CDK3, IC50: 5 nM
|
cyclin D1-CDK4, IC50: 4 nM
|
|
cyclin D3-CDK6, IC50: 55 nM
|
cyclin H-CDK7, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
ML167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK4, IC50: 136 nM
CLK1, IC50: 1522 nM
CLK2, IC50: 1648 nM
|
|
98.62% |
SEL120-34A hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
|
99.98% |
CLK1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
KH-CB19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 19.7 nM
CLK3, IC50: 530 nM
|
|
99.31% |
PROTAC CDK12/13 Degrader-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.37% |
Voruciclib |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
|
|
|
|
|
|
|
|
|
|
99.77% |
NU6102 |
Cdk1/cyclin B, IC50: 9.5 nM
|
CDK2/cyclin A3, IC50: 5.4 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
HS-243 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
CDK9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.52% |
JH-XI-10-02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
Riviciclib hydrochloride |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
|
|
|
|
|
|
98.89% |
Dalpiciclib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
YX-2-107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
DS96432529 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
Bisindolylmaleimide X hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
Dalpiciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
XY028-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
CDK5-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
AZ5576 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
Palbociclib-d8 |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
(-)-Enitociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
Senexin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
Samuraciclib hydrochloride dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
CC-671 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
CDK9-IN-2 |
|
|
|
|
|
|
|
|
CDK9, IC50: 5 nM (H929 multiple myeloma cell line)
|
|
|
|
|
|
|
|
|
|
99.37% |
EHT 5372 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 22.8 nM
CLK2, IC50: 88.8 nM
CLK4, IC50: 59.0 nM
|
|
98.12% |
Alsterpaullone |
Cdk1/cyclin B, IC50: 35 nM
|
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
Olomoucine |
|
cdk2-cyclin A, IC50: 7 μM
cdk2-cyclin E, IC50: 7 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
RSS0680 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
LY3177833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
LDC4297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
XL413 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
YKL-5-124 TFA |
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
AMG 925 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
K00546 |
Cdk1/cyclin B, IC50: 0.6 nM
|
cdk2/cyclin A, IC50: 0.5 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
|
|
98.08% |
CDK-IN-2 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 8 nM
|
|
|
|
|
|
|
|
|
|
98.97% |
FIT-039 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 5.8 μM
|
|
|
|
|
|
|
|
|
|
99.56% |
JH-XVI-178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.16% |
Casein Kinase inhibitor A86 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
CDK2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MeBIO |
Cdk1/cyclin B, IC50: 55 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
AS2863619 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
NU6140 |
CDK1-Cyclin B, IC50: 6.6 μM
|
cdk2-cyclin A, IC50: 0.41 μM
|
|
CDK4-Cyclin D, IC50: 5.5 μM
|
|
|
cdk7-cyclin H, IC50: 3.9 μM
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
Garcinone C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
Cimpuciclib tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
BSJ-01-175 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
CDK4/6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
LDC4297 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
CK7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
Longdaysin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
DB0614 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
AT7519 Hydrochloride |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
|
99.42% |
Atuveciclib Racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
CDK9-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
GW8510 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
(E/Z)-Zotiraciclib citrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.06% |
NSC 625987 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
CDK1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BGG463 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
CDK8-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
CDK4/6-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RGB-286638 free base |
cyclin B1-CDK1, IC50: 2 nM
|
cyclin E-CDK2, IC50: 3 nM
|
cyclin E-CDK3, IC50: 5 nM
|
cyclin D1-CDK4, IC50: 4 nM
|
|
cyclin D3-CDK6, IC50: 55 nM
|
cyclin H-CDK7, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
NU2058 |
|
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
NVP-LCQ195 |
Cdk1/cyclin B, IC50: 2 nM
|
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
|
CDK3/Cyclin E, IC50: 42 nM
|
|
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
|
cdk6/cyclin D3, IC50: 187 nM
|
CDK7/Cyclin H/MAT1, IC50: 3564 nM
|
|
CDK9/cyclinT1, IC50: 15 nM
|
|
|
|
|
|
|
|
|
|
98.81% |
CDK9-IN-7 |
|
|
|
CDK4/cyclin D, IC50: 148 nM
|
|
CDK6/cyclinD, IC50: 145 nM
|
|
|
CDK9/cyclinT1, IC50: 11 nM
|
|
|
|
|
|
|
|
|
|
98.05% |
Avotaciclib trihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
Ipivivint |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
CDK9-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
TP-1287 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Avotaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
GSK-3 inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
Senexin C |
|
|
|
|
|
|
|
CDK8/CycC, IC50: 3.6 nM
CDK8/CycC, Kd: 1.4 nM
|
|
|
|
|
|
|
|
|
|
|
98.06% |
Manzamine A hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
CDK8-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
Ca2+ channel agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
CA224 |
|
cdk2-cyclin A, IC50: 521 μM
|
|
cdk4-cyclin D1, IC50: 6.2 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
CDK8-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
CAN508 |
Cdk1/cyclin B, IC50: 44 μM
|
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
|
|
Cdk4/cyclin D1, IC50: 13.5 μM
|
|
|
CDK7/cyclin H, IC50: 26 μM
|
|
CDK9/cyclinT1, IC50: 0.35 μM
|
|
|
|
|
|
|
|
|
|
99.59% |
LL-K8-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
BI-1622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
CDK9 inhibitor HH1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THZ1-R |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
DB1113 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
NecroIr1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
Desmethylglycitein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.98% |
ABC1183 |
|
|
|
|
|
|
|
|
CDK9- Cyclin T1, IC50: 321 nM
|
|
|
|
|
|
|
|
|
|
99.19% |
Butyrolactone I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
GW297361 |
yeast Cdk1, IC50: 20 nM
human CDK1, IC50: 30 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
yeast Pho85, IC50: 400 nM
|
98.13% |
ON-013100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.66% |
Ribociclib succinate hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
JSH-009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
NU6027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
CDK8/19-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 0.99 nM
|
|
|
|
98.03% |
CDK12-IN-5 |
|
CDK2/cyclinE, IC50: 173 μM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 127 μM
|
|
|
|
|
|
|
|
|
|
99.01% |
(E/Z)-Zotiraciclib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
CLK1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 5 nM
CLK2, IC50: 42 nM
CLK4, IC50: 108 nM
|
|
98.03% |
Samuraciclib hydrochloride hydrate |
|
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 41 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
Voruciclib hydrochloride |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
|
|
|
|
|
|
|
|
|
|
99.23% |
CDDD11-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
CDK7-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HTH-01-091 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
CDK1-IN-1 |
CDK1/cycB, IC50: 161.2 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
PROTAC CDK12/13 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
Bohemine |
|
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 2.7 μM
|
|
|
|
|
|
|
|
|
|
98.93% |
Lacto-N-fucopentaose I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
Cdk1/2 Inhibitor III |
Cdk1/cyclin B, IC50: 2.1 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
7BIO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
Vanicoside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
5-Iodo-indirubin-3'-monoxime |
Cdk1/cyclin B, IC50: 25 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
PNU112455A hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
KH-CB20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 16.5 nM
CLK3, IC50: 488 nM
|
|
99.80% |
CDK9-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
CDK9-IN-12 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 5.41 nM
|
|
|
|
|
|
|
|
|
|
99.65% |
(R)-DRF053 dihydrochloride |
CDK1/cyclinB1, IC50: 220 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
(R)-(+)-O-Demethylbuchenavianine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
HEMTAC CDK4/6 degrader 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RGB-286147 |
CDK1/cyclinB, IC50: 48 nM
|
|
|
|
|
cdk6/cyclin D3, IC50: 232 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
NecroIr2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
CGP-82996 |
CDK1/cyclinB, IC50: >100 μM
|
CDK2/cyclinA, IC50: >50 μM
CDK2/cyclin E, IC50: >50 μM
|
|
Cdk4/cyclin D1, IC50: 1.5 μM
CDK4/cyclin D2, IC50: >50 μM
|
|
CDK6/cyclinD1, IC50: 5.6 μM
Cdk6/cyclin D2, IC50: >50 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
CDK7-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
Ryuvidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
Abemaciclib metabolite M20-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
CDK9-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
CDK7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
Lerociclib |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
|
|
|
|
|
|
98.35% |
(S)-LY3177833 hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IV-361 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
AT7519 TFA |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
|
98.53% |
LY3177833 monhydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
BS-181 |
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
(E/Z)-BIO-acetoxime |
CDK1/cyclinB, IC50: 63 μM
|
CDK2/cyclinA, IC50: 4.3 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NSC693868 |
Cdk1/cyclin B, IC50: 600 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
CDK12-IN-6 |
|
CDK2/cyclinE, IC50: >20 μM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: >20 μM
|
|
|
|
|
|
|
|
|
|
98.09% |
YKL-1-116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Akt1&PKA-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
JSH-009 dimaleate |
CDK1/cyclinB, IC50: 5410 nM
|
CDK2/cyclinA, IC50: 6850 nM
|
CDK3/cyclin E1, IC50: >10,000 nM
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 3700 nM
|
CDK8/cyclin C, IC50: >10,000 nM
|
CDK9/cyclinT1, IC50: 0.928 nM
|
|
|
|
CDK14/Cyclin Y, IC50: 2710 nM
|
CDK16/Cyclin Y, IC50: 195 nM
|
|
|
|
|
|
CLK1/2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 16 nM
CLK2, IC50: 45 nM
|
|
99.87% |
KB-0742 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 6 nM
|
|
|
|
|
|
|
|
|
|
99.38% |
AMG 925 HCl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BS-194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
Akt1&PKA-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK4/6 degrader 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
Manzamine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SEL120-34A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
|
|
Abemaciclib metabolite M18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PHA-767491 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
JA397 |
|
|
|
|
|
|
|
|
|
|
|
|
CDK14/Cyclin Y, EC50: 27.1 nM
|
CDK16/Cyclin Y, EC50: 39.0 nM
|
|
|
|
|
|
Palbociclib dihydrochloride |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Palbociclib orotate |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Samuraciclib |
|
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 41 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cimpuciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YJ1206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTS964 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZLMT-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-2 hydrochloride hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FN-1501-propionic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
HDAC1/2 and CDK2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Riviciclib |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
|
|
|
|
|
|
|
CDK6/9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senexin A hydrochloride |
|
|
|
|
|
|
|
CDK8, IC50: 280 nM
CDK8, Kd: 0.83 μM
|
|
|
|
|
|
|
|
|
|
|
|
Amantadine sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BS-181 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2/4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8 ligand 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Haspin-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(S)-LY3177833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CKI-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HDAC1/CDK7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YJ9069 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P-gp/CDK2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multi-kinase-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PT-262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
CDKI-83 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aloisine A |
CDK1/cyclinB, IC50: 0.15 μM
|
CDK2/cyclinA, IC50: 0.12 μM
CDK2/cyclinE, IC50: 0.4 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2/4/6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1/4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 9.7 nM
CLK4, IC50: 6.6 nM
|
|
|
CP-07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carbonic anhydrase inhibitor 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-21 maleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wogonin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALK-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2/4/6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-2 |
|
|
|
|
|
|
|
|
CDK9, IC50: 17 μM (MCF-7 cells)
|
|
|
|
|
|
|
|
|
|
|
CDK5-IN-4 |
|
CDK2, IC50: 6.24 ± 2.8 μM
|
|
|
CDK5, IC50: 9.8 ± 2.29 μM
|
|
|
|
CDK9, IC50: 1.76 ± 0.3 μM
|
|
|
|
|
|
|
|
|
|
|
CDK1/Cyc B-IN-1 |
CDK1-Cyclin B, IC50: 97 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
CDK9-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TMX-3013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XL413 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SLM6 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 133 nM
|
|
|
|
|
|
|
|
|
|
|
CDK2 degrader 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK5-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fascaplysin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CPD-39 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK5-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
CDK9-IN-19 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 2 nM
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-22 |
|
cdk2/cyclin A, IC50: 876.2 nM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 10.4 nM
|
|
|
|
|
|
|
|
|
|
|
SHR5428 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-20 |
|
CDK2/cyclinE, IC50: 0.219 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
ZDLD20 |
|
|
|
CDK4/CycD3, IC50: 6.51 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
IIIM-290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK/HDAC-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZLHQ-5f |
|
CDK2/CycA2, IC50: 0.145 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YY173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KDM1/CDK1-IN-1 |
CDK1, IC50: 0.078 ± 2. μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-18 |
|
|
|
Cdk4/cyclin D1, IC50: 46 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK6/PIM1-IN-1 |
CDK1/cyclinB, IC50: >10 μM
|
CDK2/cyclinA, IC50: 2.274 μM
|
CDK3/Cyclin E, IC50: >10 μM
|
Cdk4/cyclin D1, IC50: 3.6 nM
|
|
CDK6/cyclinD1, IC50: 39 nM
|
CDK7/Cyclin H/MNAT1, IC50: 393 nM
|
|
CDK9/cyclinT1, IC50: 440 nM
|
|
CDK12/Cyclin K, IC50: >10 μM
|
CDK13/Cyclin K, IC50: >10 μM
|
|
|
|
|
|
|
|
CDK7-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-7 |
|
CDK2/cyclinE, IC50: 50 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHP2/CDK4-IN-1 |
|
|
|
CDK4, IC50: 18.2 ± 1.3 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anticancer agent 30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BMI-1026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK-IN-14 |
|
CDK2/CycA2, IC50: 0.097 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
JH-VIII-49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK-TCIP1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EF-4-177 |
|
CDK2/cyclinE, IC50: 87 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SZ-015268 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-6 |
|
|
|
|
|
|
|
|
CDK942, DC50: 0.03 μM
CDK955, DC50: 0.05 μM
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9/CycT1 Degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VCC972839:01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 1.1 nM
CLK2, IC50: 2.1 nM
|
|
|
FLT3/ITD-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK16/Cyclin Y, EC50: 1768 nM
|
|
|
|
|
|
PSTAIR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4 degrader 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GSK-3 inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-Methylthienyl-carbonyl-JNJ-7706621 |
CDK1/cyclinB, IC50: 6.4 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-9 |
|
|
|
|
|
CDK6/cyclinD1, IC50: 905 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cdc7-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZLWT-37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZDLD13 |
|
|
|
CDK4/CycD3, IC50: 0.38 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK1/2/4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antitumor agent-174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anticancer agent 29 |
CDK1/cyclinB1, IC50: 0.127 μM
|
CDK2/cyclinE, IC50: 0.054 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BSJ-5-63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7/9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK12-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19 Probe 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK12-IN-4 |
|
CDK2/cyclinE, IC50: >20 μM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: >20 μM
|
|
|
|
|
|
|
|
|
|
|
Ulecaciclib |
|
cdk2/cyclin A, Ki: 0.62 μM
|
|
Cdk4/cyclin D1, Ki: 0.2 nM
|
|
|
cdk7-cyclin H, Ki: 0.63 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-28 |
|
cdk2/cyclin A, IC50: 6224 nM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: <5 nM
|
|
|
|
|
CDK13/Cyclin K, IC50: 152 nM
|
|
|
|
|
|
|
|
ZLC491 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC FLT3/CDKs degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indirubin-3'-monoxime-5-sulphonic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multi-kinase-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLZX-205 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EGFR-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LDC3140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aloisine RP106 |
Cdk1/cyclin B, IC50: 0.7 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indirubin-5-sulfonate |
Cdk1/cyclin B, IC50: 55 nM
|
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
|
|
Cdk4/cyclin D1, IC50: 300 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-5 |
|
|
|
|
|
|
|
|
CDK942, DC50: 0.10 μM
CDK955, DC50: 0.14 μM
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CPD-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Haspin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-10 |
|
|
|
|
|
CDK6/cyclinD1, IC50: 10 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARN25499 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-14-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK7-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FLT3/CDK4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK1-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8/19-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 2.49 nM
|
|
|
|
|
JTK-101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK2-IN-27 |
CDK1/cyclinB1, IC50: >10-20 nM nM
|
CDK2/cyclin E1, IC50: <10 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CCT68127 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Olomoucine II |
Cdk1/cyclin B, IC50: 7.6 μM
|
CDK2/cyclinE, IC50: 0.1 μM
|
|
CDK4/cyclinD1, IC50: 19.8 μM
|
|
|
CDK7/cyclin H, IC50: 0.45 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
CDD-2807 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK4, IC50: 85 nM
CLK2, IC50: 101 nM
CLK1, IC50: 116 nM
|
|
|
PNU-292137 |
CDK1/cyclinB, IC50: 270 nM
|
CDK2/cyclinA, IC50: 37 nM
CDK2/cyclin E, IC50: 92 nM
|
|
CDK4/cyclinD1, IC50: >10000 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(S)-Roscovitine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|